DOK7 could be targeted in combination with highly productive, SMN-inducing therapies to enhance the integrity of affected NMJs with advantage of prolonging the therapeutic window for SMA treatment [76]. This evidence concerns the gene DOK7 and proximal spinal muscular atrophy.